Zimbabwe has rejected a substantial US health deal worth 367 million US dollars (272 million pounds) spanning five years over the United States' request for sensitive information.
This rejection became public after a official document dated December was leaked, which showed President Emmerson Mnangagwa deemed the arrangement was "lopsided".
An official spokesperson later explained that the United States was demanding access to genetic material for scientific study and commercial gain while was not willing to share the benefits from future treatments.
"We are forced to start the challenging and unfortunate task of ending our support in Zimbabwe," stated American envoy to Zimbabwe Pamela Tremont in a statement.
Her embassy indicated the United States had furnished more than $1.9bn in health funding to Zimbabwe during the past two decades.
A physicians' group in Zimbabwe has urged more negotiations to secure a deal suitable to both sides so the country's critical HIV treatment initiative can proceed.
Broader Background
Zimbabwe's decision comes after a comparable situation in neighbouring Kenya, where a high court suspended a similar deal with the US following concerns were raised about the safety of citizens' medical information.
Since resuming office recently, US President Donald Trump has slashed foreign aid and shut down the key foreign aid agency.
USAID had overseen aid for the American government, but Trump stated its spending was "wasteful" and his government was pursuing government-to-government deals to boost transparency and accountability.
As per reports, Sixteen African countries have to date signed these new health pacts, representing more than $18.3bn of fresh investment.
Details of the Declined Deal
The funds for Zimbabwe was intended to gone towards "HIV/Aids treatment and prevention, TB, malaria, healthcare for mothers and children, and preparing for epidemics".
"It is our view this cooperation would have delivered extraordinary advantages for Zimbabwean communities, especially the 1.2 million currently receiving HIV treatment through US-supported initiatives," Tremont said.
However, official spokesman Nick Mangwana argued the proposed deal was "unfair".
"Zimbabwe was being asked to surrender its genetic material and health information for a long time, without any equivalent promise of access to any medical innovations – like vaccines, diagnostics, or treatments – that could be developed from that shared data," his statement read.
"Put simply, our country would provide the basic resources for medical research with no certainty that the resulting innovations would be available to our people if a future health crisis emerge."
Sovereignty and International Frameworks
He also said that the American exit from the global health body and its push of bilateral deals were undermining frameworks previously set up through the global health agency.
Mangwana cited its Pandemic Benefit-Sharing system created to deal with future pandemics.
"This mechanism is designed to ensure that when a country provides its samples, the benefits – including vaccines and treatments – are shared equitably, not commercialised solely by those with the funds to create them."
These objections regarding the US deal "are not meant as hostility towards the US," Mangwana stressed.
"We encourage further dialogue with our American counterparts on how subsequent co-operation could be structured in a way that honours the sovereignty and dignity of both nations."
Health Experts Reaction
Medical experts stated it understood the government's concerns, but suggested that talks must proceed considering a large portion of the nation's Aids initiatives relied on international support.
"If technical issues arise, such as those relating to data governance or implementation frameworks, these can often be addressed via technical clarification and negotiated safeguards," the group added.
This impasse underscores the complex tensions between receiving much-needed international aid and safeguarding national sovereignty in an increasingly interconnected world.